How well does Ziihera(Zanidatamab) work?

This section summarizes the clinical efficacy data from the pivotal trial.

Clinical Efficacy Outcomes

In the pivotal clinical trial involving patients with previously treated, HER2-positive biliary tract cancer, ZIIHERA demonstrated an objective response rate of 52%, with 3.2% achieving complete response and 48% achieving partial response. The median duration of response was 14.9 months, and 59% of responders maintained their response for at least six months, supporting its accelerated approval.